Glen Eagle Advisors’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$96 Sell
16
-30
-65% -$226 ﹤0.01% 1006
2025
Q4
$330 Sell
46
-11
-19% -$87 ﹤0.01% 1018
2025
Q3
$609 Buy
57
+12
+27% +$118 ﹤0.01% 1040
2025
Q2
$436 Sell
45
-16
-26% -$165 ﹤0.01% 992
2025
Q1
$908 Hold
61
﹤0.01% 941
2024
Q4
$910 Sell
61
-5
-8% -$81 ﹤0.01% 973
2024
Q3
$1.26K Sell
66
-25
-27% -$518 ﹤0.01% 975
2024
Q2
$1.88K Sell
91
-112
-55% -$2.23K ﹤0.01% 913
2024
Q1
$3.82K Buy
203
+5
+3% +$86 ﹤0.01% 805
2023
Q4
$2.85K Sell
198
-31
-14% -$422 ﹤0.01% 821
2023
Q3
$3.98K Sell
229
-6
-3% -$125 ﹤0.01% 760
2023
Q2
$4.89K Buy
235
+19
+9% +$413 ﹤0.01% 740
2023
Q1
$5.08K Sell
216
-14
-6% -$376 ﹤0.01% 712
2022
Q4
$6.42K Sell
230
-246
-52% -$6.29K ﹤0.01% 674
2022
Q3
$11.1K Sell
476
-52
-10% -$1.57K ﹤0.01% 580
2022
Q2
$17.8K Buy
528
+21
+4% +$736 ﹤0.01% 523
2022
Q1
$17.7K Sell
507
-51
-9% -$1.74K ﹤0.01% 531
2021
Q4
$17K Sell
558
-188
-25% -$6.12K ﹤0.01% 531
2021
Q3
$24.1K Sell
746
-12
-2% -$384 0.01% 522
2021
Q2
$22.9K Buy
+758
New +$25K 0.01% 530

Other funds holding OGN

Glen Eagle Advisors's OGN Position: Q1 2026 in Review

Glen Eagle Advisors reduced its Organon & Co (OGN) stake by 65% in Q1 2026, selling an estimated $226 and leaving 16 shares worth $96. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

Glen Eagle Advisors first reported a position in OGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $24.1K in Q3 2021. 603 funds tracked by Wall St. Rank hold OGN as of Q1 2026.

  • Glen Eagle Advisors held 16 shares of Organon & Co worth $96 as of Q1 2026.
  • Glen Eagle Advisors sold 30 Organon & Co shares in Q1 2026, an estimated $226.
  • Organon & Co made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #1006 holding.
  • Glen Eagle Advisors first reported a position in Organon & Co in Q2 2021 and has held it in 20 quarters since.
  • Glen Eagle Advisors's Organon & Co position peaked at $24.1K in Q3 2021.
  • 603 funds tracked by Wall St. Rank held Organon & Co as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.